超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

Mallinckrodt   
Covidien的制藥業(yè)務(wù)部Mallinckrodt提供用于疼痛及相關(guān)疾病診斷程序和治療的產(chǎn)品，是該領(lǐng)域垂直整合的領(lǐng)先企業(yè)。該公司是美國(guó)領(lǐng)先的鴉片類止痛藥供應(yīng)商、活性藥物成份的領(lǐng)先制造商。該公司還是美國(guó)一家主要的醫(yī)用同位素锝-99m的供應(yīng)商、放射藥品和造影劑及給藥系統(tǒng)的業(yè)界領(lǐng)導(dǎo)廠商。2012年銷售額為20億美元。
    

Mallinckrodt, the Pharmaceuticals business of Covidien, is a vertically integrated leader in providing products used in diagnostic procedures and in the treatment of pain and related conditions. We are the largest U.S. supplier, by prescription, of opioid pain medications and a leading manufacturer of active pharmaceutical ingredients. We are also the largest global supplier of the medical isotope technetium-99m and an industry leader in radiopharmaceuticals, contrast media, and delivery systems. Mallinckrodt encompasses more than 5,500 dedicated employees around the globe, all focused on our core values of quality, integrity and service to meet the needs of patients globally.

Established as G. Mallinckrodt & Company in 1867, the $2 billion St. Louis-based business was acquired by Tyco International in 2000. In 2007, Tyco spun off its healthcare business into Covidien, a leading global healthcare products company. On December 15, 2011, Covidien announced plans to spin off Mallinckrodt as a standalone public company. The Company expects to complete the spin-off by mid-2013.

Mallinckrodt’s mission is to reveal and relieve disease for a healthier world, and our vision expands on our mission – a world made healthier by building on our heritage of distinctive capabilities to provide patients with pharmaceuticals that reveal and relieve disease.